E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Idiopathic Pulmonary Fibrosis (IPF) |
Fibrose Pulmonaire Idiopathique (IPF) |
|
E.1.1.1 | Medical condition in easily understood language |
Fibrosis of the lungs of unidentified origin |
Fibrose des poumons d'origine non identifiée |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10021240 |
E.1.2 | Term | Idiopathic pulmonary fibrosis |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to demonstrate a reduction in lung function decline as measured by the change from baseline in FVC for BI 1015550 when compared to placebo in patients with IPF. |
L'objectif principal est de démontrer une diminution du déclin de la fonction pulmonaire, mesurée par le changement par rapport à l’état initial de la Capacité Vitale Forcée (CVF), avec le BI 1015550 par rapport au placebo chez les patients atteints de FPI. |
|
E.2.2 | Secondary objectives of the trial |
The main secondary objective of the trial is to demonstrate BI 1015550’s ability in reducing the occurrence of clinically meaningful events such as acute IPF exacerbation, hospitalization for respiratory cause or death over the duration of the trial when compared to placebo in patients with IPF. An additional secondary objective of the trial is to show an effect of BI 1015550 on symptoms and lung function. |
L'objectif secondaire principal est de démontrer la capacité du BI 1015550 à réduire la survenue d'événements cliniquement significatifs tels que les exacerbations aiguës de FPI, les hospitalisations pour cause respiratoire ou les décès pendant la durée de l'étude par rapport au placebo chez les patients atteints de FPI. Un autre objectif secondaire de l'essai est de montrer un effet du BI 1015550 sur les symptômes et la fonction pulmonaire. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients ≥40 years old at the time of signed consent IPF diagnosis based on 2022 ATS/ERS/JRS/ALAT Guidelines FVC ≥45% of predicted normal DLCO ≥25% and <90% predicted of normal On stable treatment with nintedanib or pirfenidone for at least 12 weeks or not on treatment with either nintedanib or pirfenidone for at least 8 weeks |
Patients ≥40 ans au moment de la signature du consentement Diagnostic de FPI basée sur les guidelines 2022 ATS/ERS/JRS/ALAT CVF ≥45% de la valeur normale prédite DLCO ≥25% et <90% de la valeur normale prédite Traités par nintedanib ou pirfenidone stable depuis au moins 12 semaines ou non traités par nintedanib ou pirfenidone au cours des 8 dernières semaines |
|
E.4 | Principal exclusion criteria |
Relevant airways obstruction (prebronchodilator FEV1/FVC <0.7) Acute IPF exacerbation within 3 months and/or during the screening period Treated with immunomodulatory medications (other than oral corticosteroids) or prednisone >15 mg/day or equivalent for respiratory or pulmonary reasons Active, unstable or uncontrolled vasculitis within 8 weeks Any suicidal behaviour in the past 2 years Any suicidal ideation of type 4 or 5 on the C-SSRS in the past 3 months |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the absolute change from baseline in Forced Vital Capacity (FVC) [mL] at Week 52. |
Changement en valeur absolue par rapport à l’état initial de la CVF (mL) à la Semaine 52 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1) key secondary endpoint: time to the first occurrence of any of the components of the composite endpoint: time to first acute IPF exacerbation, first hospitalization for respiratory cause, or death (whichever occurs first) over the duration of the trial 2) Time to first acute IPF exacerbation or death over the duration of the trial 3) Time to hospitalization for respiratory cause or death over the duration of the trial 4) Time to absolute decline in FVC % predicted of >10% from baseline or death over the duration of the trial 5) Time to absolute decline in (DLCO) % predicted of >15% from baseline or death over the duration of the trial 6) Time to death over the duration of the trial 7) Absolute change from baseline in Living with Pulmonary Fibrosis (LPF) Symptoms Dyspnea domain score at Week 52 8) Absolute change from baseline in Living with Pulmonary Fibrosis (LPF) Symptoms Cough domain score at Week 52 9) Absolute change from baseline in Living with Pulmonary Fibrosis (LPF) Symptoms Fatigue domain score at Week 52 10) Absolute change from baseline in FVC % predicted at Week 52 11) Absolute change from baseline in DLCO % predicted at Week 52 |
1) Critère secondaire principal : délai avant la première survenue de l’un des composants du critère composite : délai avant la première exacerbation aiguë de FPI, avant la première hospitalisation pour cause respiratoire, ou décès (quel que soit le premier qui survient) pendant toute la durée de l’étude. 2) Délai avant la première exacerbation aigüe de FPI ou décès pendant la durée de l'étude 3) Délai avant hospitalisation pour cause respiratoire ou décès pendant la durée de l'étude 4) Délai avant le déclin absolu >10% de la CVF en % de la valeur prédite par rapport à l'état initial ou décès pendant la durée de l'étude 5) Délai avant le déclin absolu >15% de la DLCO en % de la valeur prédire par rapport à l'état initial ou décès pendant la durée de l'étude 6) Délai avant décès pendant la durée de l'étude 7) Changement absolu par rapport à l'état initial du score du domaine Symptômes Dyspnée du questionnaire Living with Pulmonary Fibrosis (LPF) à la semaine 52 8) Changement absolu par rapport à l'état initial du score du domaine Symptômes Toux du questionnaire Living with Pulmonary Fibrosis (L-PF) à la semaine 52 9) Changement absolu par rapport à l'état initial du score du domaine Symptômes Fatigue du questionnaire Living with Pulmonary Fibrosis (LPF) à la semaine 52 10) Changement absolu par rapport à l'état initial de la CVF en % de la valeur prédite à la semaine 52 11) Changement absolu par rapport à l'état initial de la DLCO en % de la valeur prédite à la semaine 52
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) 30 months 2) 30 months 3) 30 months 4) 30 months 5) 30 months 6) 30 months 7) 52 weeks 8) 52 weeks 9) 52 weeks 10) 52 weeks 11) 52 weeks |
1) 30 mois 2) 30 mois 3) 30 mois 4) 30 mois 5) 30 mois 6) 30 mois 7) 52 semaines 8) 52 semaines 9) 52 semaines 10) 52 semaines 11) 52 semaines |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 164 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Brazil |
Canada |
Chile |
China |
Egypt |
India |
Israel |
Japan |
Korea, Republic of |
Malaysia |
Mexico |
New Zealand |
Saudi Arabia |
Singapore |
South Africa |
Taiwan |
Thailand |
United States |
Austria |
Estonia |
Finland |
France |
Poland |
Sweden |
Netherlands |
Spain |
Switzerland |
Czechia |
Germany |
Greece |
Italy |
Belgium |
Croatia |
Denmark |
Georgia |
Hungary |
Ireland |
Norway |
Portugal |
Serbia |
Slovenia |
Turkey |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Dernière visite du dernier patient |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 4 |